Fuchs, Kornelius and Rummler, Silke and Ries, Wolfgang and Helmschrott, Matthias and Selbach, Jochen and Ernst, Friedlinde and Morath, Christian and Gauly, Adelheid and Atiye, Saynab and Stauss-Grabo, Manuela and Giefer, Mareike (2022) Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications. THERAPEUTIC APHERESIS AND DIALYSIS, 26 (1). pp. 229-241. ISSN 1744-9979, 1744-9987
Full text not available from this repository. (Request a copy)Abstract
Immunoadsorption is well known to selectively remove immunoglobulins and immune complexes from plasma and is applied in a variety of autoimmune diseases and for desensitization before, or at acute rejection after organ transplantation. Performance, safety, and clinical effectiveness of immunoadsorption were the aim of this study. This prospective, noninterventional, multicentre cohort study included patients treated with immunoadsorption (Immunosorba or GLOBAFFIN adsorbers) for any indication. Clinical effectiveness was assessed after termination of the patient's individual treatment schedule. Eighty-one patients were included, 69 were treated with Immunosorba, 11 with GLOBAFFIN, one patient with both adsorbers. A majority of patients was treated for neurological indications, dilated cardiomyopathy, and before or after kidney or heart transplantation. Mean IgG reduction from pre- to post-treatment was 69.9% +/- 11.5% for Immunosorba and 74.1% +/- 5.0% for GLOBAFFIN, respectively. The overall IgG reduction over a complete treatment block was 68%-93% with Immunosorba and 62%-90% with GLOBAFFIN depending on the duration of the overall treatment. After termination of the immunoadsorption therapy, an improvement of clinical status was observed in 63.0%, stabilization of symptoms in 29.6%, and a deterioration in 4.9% of patients. Changes in fibrinogen, thrombocytes, and albumin were mostly classified as noncritical. Overall, the treatments were well tolerated. Immunoadsorption in routine clinical practice with both GLOBAFFIN and Immunosorba has been safely performed, was well tolerated by patients, and effective in lowering immunoglobulins with an improvement or maintenance of clinical status, thus represents an additional therapeutic option for therapy refractory immune disorders.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PLASMA-EXCHANGE; THERAPEUTIC APHERESIS; MYASTHENIA-GRAVIS; UPDATE; SUBSTITUTION; EFFICACY; clinical effectiveness; dilated cardiomyopathy; immunoadsorption; neurology; transplantation |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Sep 2022 05:29 |
| Last Modified: | 27 Sep 2022 05:29 |
| URI: | https://pred.uni-regensburg.de/id/eprint/47981 |
Actions (login required)
 |
View Item |
